Pacira BioSciences Inc

NASDAQ:PCRX   3:59:51 PM EDT
52.94
-1.01 (-1.87%)
Products, Regulatory

Pacira Biosciences Announces Positive Topline Data From Phase 3 Study Of Exparel As A Single-Dose Femoral Nerve Block In Adductor Canal For Total Knee Arthroplasty

Published: 09/07/2022 11:27 GMT
Pacira BioSciences Inc (PCRX) - Pacira Biosciences Announces Positive Topline Data From Phase 3 Study of Exparel As a Single-dose Femoral Nerve Block in Adductor Canal for Total Knee Arthroplasty.
Pacira Biosciences Inc - Exparel Was Well Tolerated With a Safety Profile Consistent With Bupivacaine Hcl.
Pacira - Plans to Submit a Snda to U.S. FDA Early Next Year Seeking Expansion of Exparel Label to Include Femoral Nerve Block in Adductor Canal.